ABT-737

For research use only. Not for use in humans.

目录号:S1002

ABT-737 Chemical Structure

CAS No. 852808-04-9

ABT-737是一种BH3模拟抑制剂,作用于Bcl-xLBcl-2Bcl-w,无细胞试验中EC50分别为78.7 nM,30.3 nM和197.8 nM;但对Mcl-1, Bcl-B及Bfl-1没有抑制作用。ABT-737可诱导线粒体通路的凋亡和线粒体自噬。Phase 2。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 3144.65 现货
RMB 972.14 现货
RMB 1647.36 现货
RMB 4659.22 现货
RMB 7964.03 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的ABT-737发表文献272篇:

产品安全说明书

Bcl-2抑制剂选择性比较

生物活性

产品描述 ABT-737是一种BH3模拟抑制剂,作用于Bcl-xLBcl-2Bcl-w,无细胞试验中EC50分别为78.7 nM,30.3 nM和197.8 nM;但对Mcl-1, Bcl-B及Bfl-1没有抑制作用。ABT-737可诱导线粒体通路的凋亡和线粒体自噬。Phase 2。
特性 ABT-737是第一代抗凋亡BCL-2家族蛋白小分子抑制剂。
靶点
Bcl-2 [1]
(Cell-free assay)
Bcl-xL [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
Bcl-B [1]
(Cell-free assay)
30.3 nM(EC50) 78.7 nM(EC50) 197.8 nM(EC50) 1.82 μM(EC50)
体外研究

ABT-737降低BCL-2/BAX异质二聚体,而诱导HL60细胞凋亡,但是对细胞周期分布没有抑制效果。ABT-737也诱导细胞色素C从线粒体中释放,促进BAX构象改变,BAX与凋亡相关。在白血病模型中,ABT-737按30 mg/kg处理,阻断53%白血病负荷,且使鼠寿命明显延长。ABT-737不会导致血细胞数和血清组成发生异常。[1]通过使Mcl-1失活而使抵抗细胞(Hela和MCF-7)对ABT-737敏感。当Mcl-1无效时,ABT-737也导致BAX/BAK-依赖的细胞色素C释放。ABT-737延长携带BCL-2肿瘤的鼠寿命。[2]ABT-737从BCL2’s BH3结合袋取代BIM,使BIM激活BAX,诱导线粒体透化作用,快速致死慢性淋巴细胞性白血病(CLL)细胞。[3] Noxa正向调节增强H196细胞对ABT-737敏感性。ABT-737抑制多种SCLC细胞系,包括NCI-H889, NCI-H1963, NCI-H1417, NCI-H146等的增殖,并诱导细胞凋亡。最近研究显示,ABT-737作用于ATLL细胞,明显诱导HTLV-1感染的T细胞凋亡。ABT-737按100 mg/kg剂量作用于ATLL鼠模型显示出强抗癌活性。[5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OCI-Ly1  M{nOc2NmdGxiVnnhZoltcXS7IFHzd4F6 NYG3WllZOjVyIH7NxsA> NGLQ[204OiCq NIDLUYRFVVOR MnfFZ4F2e2WmIEm3KUBtd3O|IH;mJJZq[WKrbHn0fUBqdiClZXzsd{B1emGwc3\lZ5Rm\CC5aYToJGJEVDZic3nSUmE> MofKNlY3PTd{OEi=
KG1a MnXOR4VtdCCYaXHibYxqfHliQYPzZZk> NF7jOooxNTFyIN88US=> NVPP[mNZOjRiaB?= MkfLSG1UVw>? MUTJR|UxRTdwNkig{txONCCmZXPy[YF{\XNiY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MYqyOlU2OjdzMh?=
Kasumi-1 MkDJR4VtdCCYaXHibYxqfHliQYPzZZk> M2rkPFAuOTBizszN Mo\4NlQhcA>? NVLtfGRITE2VTx?= M{jiVGlEPTB;ND64O{DPxE1uIHTlZ5Jm[XOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M1TlZVI3PTV{N{Gy
KG1a NGXzO3NCeG:ydH;zbZMhSXO|YYm= NXm5dIY6OC1zMDFOwG0> NFP6S3MzPCCq NXToNIJ3TE2VTx?= NWDLRmRmcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M3rR[|I3PTV{N{Gy
Kasumi-1 M3\LRmFxd3C2b4Ppd{BCe3OjeR?= M1HsUVAuOTBizszN MWqyOEBp M13wfmROW09? M2X0Volv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NWPLXoVZOjZ3NUK3NVI>
MC-3  MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfsdWc2NzFyL{KwJO69VQ>? Mn\BNlQhcA>? MYHEUXNQ NEXC[ZBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Ml3mNlY1PDd4MUW=
HN22  NXfrWIZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUiyMlUwPy53L{KyMlUh|ryP MVSyOEBp NGrienRFVVOR NHrUPJlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Mmn5NlY1PDd4MUW=
MC-3  NFuyeZZCeG:ydH;zbZMhSXO|YYm= NY[4PWczPS9zMD:yNEDPxE1? MnrvNlQhcA>? MVLEUXNQ NIL6eJlqdmS3Y3XzJINie3Cjc3WtcYVlcWG2ZXSgZZBweHSxc3nz M4m3c|I3PDR5NkG1
HN22  M{DzZ2Fxd3C2b4Ppd{BCe3OjeR?= MWCyMlUwPy53L{KyMlUh|ryP NYixU5EzOjRiaB?= Mo\sSG1UVw>? MnvjbY5lfWOnczDjZZNx[XOnLX3l[IlifGWmIHHwc5B1d3Orcx?= M3nTOVI3PDR5NkG1
MOLT-4 NEDYfnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHxW|lNOTBvNUCwNEBvVQ>? M3;0WFczKGh? MlPsSG1UVw>? MmrVTWM2OD1yLkG5PEDPxE1? M4rqdVI3Ozl{M{Oy
RS4;11 Mn3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzwOpAyOC13MECwJI5O NF;sW5g4OiCq NXW1dlF5TE2VTx?= MmTBTWM2OD1yLkCwNkDPxE1? M2ewbVI3Ozl{M{Oy
JURKAT NFzpUGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzK[2VXOTBvNUCwNEBvVQ>? NFTkVm04OiCq NGG3ZmNFVVOR NXG1ZlJ4UUN3ME22OkDPxE1? NHfBRWIzPjN7MkOzNi=>
CEM R NHfqV4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHr6fpYyOC13MECwJI5O NXnFcI9iPzJiaB?= NIDSUW1FVVOR MVXJR|UxRTVwNDFOwG0> M{CyUlI3Ozl{M{Oy
CEM S NXXjd2pWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;ZVVExNTVyMECgcm0> MUm3NkBp NH3u[FZFVVOR NXzjR3A5UUN3ME2xNk4yKM7:TR?= NULBSFgzOjZ|OUKzN|I>
MOLT-4 NVP6S29uSXCxcITvd4l{KEG|c3H5 MlO4NVAuOTByMDDuUS=> NGr2O|QzPCCq MnrRSG1UVw>? MWDjZZV{\XNidHjlJINt\WG4YXflJI9nKEKlbD2yJIFv\CC2aHWg[I94dnKnZ4XsZZRqd25ib3[gRoNtNXiOIHHu[EBO[2xvMR?= M1O0eFI3Ozl{M{Oy
CEM S NFmwVnZCeG:ydH;zbZMhSXO|YYm= NHuyS5oyOC1zMECwJI5O MonxNlQhcA>? NEfhZlhFVVOR NGjFN4Jk[XW|ZYOgeIhmKGOuZXH2ZYdmKG:oIFLjcE0zKGGwZDD0bIUh\G:5boLl[5Vt[XSrb36gc4YhSmOuLYjMJIFv\CCPY3ytNS=> MUGyOlM6OjN|Mh?=
JURKAT MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4WxW|ExOC1zMECwJI5O NXL1S49IPDhiaB?= NEHxb2JFVVOR NULxNmtrUUN3ME25OVXDuTlwMzDuUS=> MWKyOlE4OjJ4OR?=
LOUCY NIG1[IlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknTNVAxNTFyMECgcm0> Mn;lOFghcA>? NVfmTYtqTE2VTx?= NYHSbmJqUUN3ME2zNk45yrFzMD65JI5O NHX6b|IzPjF5MkK2PS=>
WM-115 M3HJVWNmdGxiVnnhZoltcXS7IFHzd4F6 M2n0T|ExOMLibl2= MkXTO|IhcA>? MmCw[Y5p[W6lZYOgZ5Vz[3WvaX6tbY5lfWOnZDDhcpRqNXO3co\peoFtyqB? MV[yOlEyPjd5Nh?=
B16 M2TrRmNmdGxiVnnhZoltcXS7IFHzd4F6 MmTONVAxyqCwTR?= MUO3NkBp NF7pb2FmdmijbnPld{BkfXKldX3pck1qdmS3Y3XkJIFvfGlvc4Xyeol3[W{EoB?= MmfNNlYyOTZ5N{[=
HL-60  NF\ZVmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVK3NkBp NHiwdoRKSzVywrC9JFExNjdibl2= MXWyOlA1PTZyOR?=
MOLM-13  MnPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LmdFczKGh? MonQTWM2OMLiPTCyO{46KG6P MoGzNlYxPDV4MEm=
OCI-AML3 NHrTVXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPaNpRsPzJiaB?= MlzxTWM2OMLiPTCxPVUxKG6P M3H5NlI3ODR3NkC5
BCWM.1 M4DON2Fxd3C2b4Ppd{BCe3OjeR?= MWqwMVEvPiEQvF2= NHLafHozPCCq MYLpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M3HxV|I2QDl|Mkmw
MWCL-1 M3;WSGFxd3C2b4Ppd{BCe3OjeR?= MXGwMVEvPiEQvF2= MlfWNlQhcA>? M1HYRYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NGHIcoQzPTh7M{K5NC=>
MM.1s M1TPfWFxd3C2b4Ppd{BCe3OjeR?= NU\1S|NbOC1zLk[g{txO NIf6SIEzPCCq MYXpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NWf4UZkxOjV6OUOyPVA>
HCT116 Mm\OSpVv[3Srb36gRZN{[Xl? MUOzM|ExKM7:TR?= NXP6NJJ5OTMEoHlCpC=> NIHIZnFFVVOR MoHXbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJGxEO0JvSVmgZ49vfmW{c3nvckBidmRiU2HTWG0yKGSnZ4Lh[IF1cW:w NI\yWWszPTdzNUCyPC=>
HCT116 BAX BAK1 DKO NEDh[5dHfW6ldHnvckBCe3OjeR?= NYXZPY06Oy9zMDFOwG0> NFHSUI4yOsLiaNMg NVzSbodsTE2VTx?= M3P1VYlv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDpcoNz\WG|ZTDpckBNSzOELVnJJINwdn[ncoPpc44h[W6mIGPRV3ROOSCmZXfyZYRifGmxbh?= MmHrNlU4OTVyMki=
HCT116 MXfGeY5kfGmxbjDBd5NigQ>? M1u1TVExKM7:TR?= M{[yOVEzyqCqwrC= M1nFTWROW09? M2ThVYlv[3KnYYPld{BITlBvTFOzRkBxfW6ldHG= M{fQNlI2PzF3MEK4
HCT116 BAX BAK1 DKO MYLGeY5kfGmxbjDBd5NigQ>? NI\YTmMyOCEQvF2= NI[1Z|AyOsLiaNMg MnnwSG1UVw>? NVzFfnpScW6lcnXhd4V{KEeIUD3MR|NDKHC3bnP0ZS=> M1XxO|I2PzF3MEK4
HCT116 NV;obHpVSXW2b4DoZYd6KEG|c3H5 MX2xNEDPxE1? MoTDNVLDqGkEoB?= MWnEUXNQ NGjwc3pqdmS3Y3XzJIEh[2:vcHzleIUh[XW2b4DoZYdq[yC{ZYPwc45{\Q>? NV7YXYsxOjV5MUWwNlg>
HCT116 BAX BAK1 DKO M1PFR2F2fG:yaHHnfUBCe3OjeR?= MXqxNEDPxE1? MnvvNVLDqGkEoB?= M{e3bmROW09? M2rMWYlv\HWlZYOgZUBkd22ybHX0[UBifXSxcHjh[4lkKHKnc4DvcpNm MWiyOVcyPTB{OB?=
U937 NXHHcGFTSXCxcITvd4l{KEG|c3H5 MV[wMlEzPS1{IN88US=> MX6yOEBp NIPOVWlmdmijbnPld{BFUEFxWD2xNU1qdmS3Y3XkJIFxd3C2b4Ppdy=> NYfJ[JRMOjV5MUSwNlQ>
U937  Mn7iRZBweHSxc3nzJGF{e2G7 M1fWVlAvPSEQvF2= MYCyOEBp NWPoPHV2\W6qYX7j[ZMh[2ynYY\h[4Uhd2ZiUFHSVEBidmRiY3HzdIF{\S1|IHHzJJdmdGxiYYOgUo95[SCuZY\lcC=> MmnWNlU4OTRyMkS=
HL-60 AAA-Bcl-2 MWDBdI9xfG:|aYOgRZN{[Xl? M2XFfFAuPSEQvF2= NGPYcXk1QCCq MULJR|UxRTBwOEeg{txu97zOaX7keYNmeyClZXzsJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MnjtNlU4OTF2NkC=
HL-60 EEE-Bcl-2 MX;BdI9xfG:|aYOgRZN{[Xl? NYjrWY04OC13IN88US=> NFn3W3I1QCCq NIj4bHJKSzVyPUWg{txu97zOIHnu[JVk\XNiY3XscEBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NGniRXkzPTdzMUS2NC=>
U87 Mn\TSpVv[3Srb36gRZN{[Xl? NI\rW2s2OCEQvF2= NYqyT2w{OjRiaB?= NIrNPG5z\WS3Y3XzJJRp\SCvUl7BJIV5eHKnc4Ppc44hdGW4ZXzzJI9nKE2PUD2yMEBOVVBvMUSgZY5lKEKlbD2y NFv3N5AzPTZ4N{[2Ny=>
K562 NEO0N3hE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MmrWNU0yOCEQvF2= M33XdFQ5KGh? M{PzUWROW09? NV7YU2hbUUN3ME2yOk44KM7:TR?= MlfHNlU2QTZ3NkG=
K562/Mcl -1-IRESBim MmOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTlwMzFOwG0> NF[2SmYzPTV|NUmwNC=>
K562/Bcl- 2-IRESBim M1HYeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fjVmlEPTB;MD6zOUDPxE1? NW\rZopKOjV3M{W5NFA>
Jurkat M3;MeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3m1dmlEPTB;MD62OkDPxE1? NYP1bGxzOjV3M{W5NFA>
JurkatΔBak NIm0Z4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV61OFl7UUN3ME61NEDPxE1? MUOyOVU{PTlyMB?=
HL60/VCR NHLFOZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLSZVJEUUN3ME6xNFAh|ryP MmH0NlU2OzV7MEC=
Kasumi-1 NW\sTIEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;rTWM2OD1yLkCxJO69VQ>? NFrwOnAzPTV|NUmwNC=>
Kasumi-1/ABT MnL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwNUGg{txO MnTlNlU2OzV7MEC=
THP-1 MmjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljTTWM2OD1zLkK3JO69VQ>? MljvNlU2OzV7MEC=
U937 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYn1fXd[UUN3ME21MlI6KM7:TR?= NViwT3RYOjV3M{W5NFA>
C1498 Mn3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTZwMUOg{txO NVvwPZBGOjV3M{W5NFA>
RPMI 8226 Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\4eGlEPTB;MD6yOUDPxE1? M2XlVlI2PTN3OUCw
MM.1S M1zFZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTBwNECg{txO NVqxe402OjV3M{W5NFA>
NCI-H929 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXETWM2OD1zNT6yNUDPxE1? NFrPb3AzPTV|NUmwNC=>
U266 M4q5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jseGlEPTB;MD62PEDPxE1? NWfQeG1WOjV3M{W5NFA>
MCF-7 NYLLSYZQS2WubDDWbYFjcWyrdImgRZN{[Xl? M{jJWlUh|ryP NYnlfpVnPDhiaB?= NW\Ne|ZPTE2VTx?= MUDlcohidmOnczD0bIUhe2Wwc3n0bZZqfHlidH:gc5IhemGmaXH0bY9v M2HSeVI2PDB7MUK0
MCF-7 MWLBdI9xfG:|aYOgRZN{[Xl? MmnDOUDPxE1? M2m0clQwOjRxNEigbC=> NF7p[npFVVOR M3f6Nolv[3KnYYPld{B1cGViY3zlZZZm\CCSQWLQ NV;aSIVyOjV2MEmxNlQ>
MCF-7 NX3IfmhCTnWwY4Tpc44hSXO|YYm= M2LBO|Uh|ryP M3\yVFI1KGh? M3v3OmROW09? NVnmZpFt\W6qYX7j[ZMhfGinbHX2[Ywhd2ZiTXPsMVEh\XiycnXzd4lwdsLi Mo\aNlU1ODlzMkS=
MDA-MB 231  M{DMXGZ2dmO2aX;uJGF{e2G7 NX73Rmc6PSEQvF2= MmXzNlQhcA>? MYPEUXNQ NVrYeoZp\W6qYX7j[ZMhfGinbHX2[Ywhd2ZiTXPsMVEh\XiycnXzd4lwdsLi NELlWVczPTRyOUGyOC=>
ZR-75-1  M{DqbWZ2dmO2aX;uJGF{e2G7 M3LKNlUh|ryP M3LH[lI1KGh? NInRW3pFVVOR NGPUbGVmdmijbnPld{B1cGWuZY\lcEBw\iCPY3ytNUBmgHC{ZYPzbY9vyqB? MVKyOVQxQTF{NB?=
A549 M1frNmNmdGxiVnnhZoltcXS7IFHzd4F6 M1LyfFAuOjBizszN MnK4O|IhcA>? NXXNbGxyTE2VTx?= M17F[4Rm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5? NGTpTGgzPTN6OEe2Ni=>
H1299 NWPBV5pWS2WubDDWbYFjcWyrdImgRZN{[Xl? NEfxNWYxNTJyIN88US=> NI\SfIU4OiCq Mle5SG1UVw>? NIXHU2hl\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw NHrz[XUzPTN6OEe2Ni=>
HO-8910 M3HJZmNmdGxiVnnhZoltcXS7IFHzd4F6 M3zUXlAuOjBizszN NEjVU5A4OiCq NYDKbVFjTE2VTx?= NHnjZppl\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw NInNb2EzPTN6OEe2Ni=>
HT-29 NX\HW2EzS2WubDDWbYFjcWyrdImgRZN{[Xl? M12yflAuOjBizszN MmrOO|IhcA>? MWXEUXNQ MnXB[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>? NXiwN2p7OjV|OEi3OlI>
HCT-116 MUnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M4q1RlAuOjBizszN NWXudFRwPzJiaB?= NHvrT2JFVVOR NVHtSlF6\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKGOxbXLpcoVlKHerdHigZZNxcXKrbh?= M1uwb|I2Ozh6N{[y
A549 M3XtVmFxd3C2b4Ppd{BCe3OjeR?= NEnGW|EzOCEQvF2= MWG0PEBp Mn\VSG1UVw>? MnrFbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJIF{eGm{aX6= M1PmXlI2Ozh6N{[y
H1299 MVfBdI9xfG:|aYOgRZN{[Xl? MnjnNlAh|ryP M3q5T|Q5KGh? MXjEUXNQ MnnxbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJIF{eGm{aX6= NYHCS2xJOjV|OEi3OlI>
Sc-1 NFz4blZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MlPCNE4xODBzLUGg{txO MmPxPVYhcA>? MX3k[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NFHuUJozPTN5M{WwPC=>
OcI-LY18 M1X5OWNmdGxiVnnhZoltcXS7IFHzd4F6 M1PLWlAvODByMT2xJO69VQ>? NWnGNYx5QTZiaB?= NWLF[pRF\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MnXNNlU{PzN3MEi=
RL  MnXER4VtdCCYaXHibYxqfHliQYPzZZk> NXvWPFQyOC5yMECxMVEh|ryP MljjPVYhcA>? NV3yemtT\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MYiyOVM4OzVyOB?=
RKO NEDBO2dE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NH7IPZkxNTFyIN88US=> Mn;rNlTjiImqwrC= MkjpSG1UVw>? NGTu[WpKSzVyPvMAjVI26oDLwsXN MXqyOVMxPDN6Mx?=
Caco-2 NITzdVFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MXKwMVExKM7:TR?= NWDiUJRKOjUkgJnoxsA> NHf0RYRFVVOR MlfQTWM2OD1zOT635qCKyrWP M2fobFI2OzB2M{iz
DLD1 MU\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NXjwZYhGOC1zMDFOwG0> MnPpNlTjiImqwrC= M4rENWROW09? NF3FdVRKSzVyPUG4Mlc56oDLwsXN MX:yOVMxPDN6Mx?=
LS411N M{Xk[GNmdGxiVnnhZoltcXS7IFHzd4F6 M1PWZVAuOTBizszN M1K3dVI16oDLaNMg NWXpdnJrTE2VTx?= NUTsdo9RUUN3ME2xNU41P+LCidM1US=> MX2yOVMxPDN6Mx?=
SW620 MnPlR4VtdCCYaXHibYxqfHliQYPzZZk> MnTENE0yOCEQvF2= NH7MeYwzPOLCiXlCpC=> NUiyNIplTE2VTx?= M{[xPWlEPTB;MUKuNlTjiIoEtV2= NWPUfJhsOjV|MESzPFM>
HCT116 M2Pq[mNmdGxiVnnhZoltcXS7IFHzd4F6 MorCNE0yOCEQvF2= MUWyOQKBkWkEoB?= NEDSWZBFVVOR MofRTWM2OD1{MD60PgKBkcL3TR?= NF:3VJIzPTNyNEO4Ny=>
HaCaT M3ziTGNmdGxiVnnhZoltcXS7IFHzd4F6 MWSwMlEwOS9zMDFOwG0> MV2yOEBp NYCxcHp6TE2VTx?= M1X5SoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NVXYdHA5OjV{MUC3PVU>
A5-RT3 MlPsR4VtdCCYaXHibYxqfHliQYPzZZk> MnnKNE4yNzFxMUCg{txO M4niO|I1KGh? NIfoSYxFVVOR MUXk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NIe2OJIzPTJzMEe5OS=>
HaCaT NGXxNldHfW6ldHnvckBCe3OjeR?= NWW5ZmJyOTEkgJpOwG0> M1Hqd|I1NzR6IHi= MVrEUXNQ MmfqbY5lfWOnczDNUXAh[W6mIFTORUBnemGpbXXueIF1cW:w MlT3NlUzOTB5OUW=
A5-RT3 NF;1WIdHfW6ldHnvckBCe3OjeR?= MYGxNQKBkc7:TR?= MX[yOE81QCCq MmLzSG1UVw>? NXHJV2lWcW6mdXPld{BOVVBiYX7kJGRPSSCocnHncYVvfGG2aX;u M{DKbFI2OjFyN{m1
A5-RT3 MYTGeY5kfGmxbjDBd5NigQ>? MUK1JO69VQ>? Mm\6OkBp MmPVSG1UVw>? Mn3FbY5lfWOnczD0bIUhemWuZXHz[UBw\iCvaYTvZ4hwdmS{aXHsJJBzd3SnaX7zJIFv\CC{ZXT1Z4V{KGOub37v[4VvcWNic4Xyeol3[WxiaX6gZUBk[XOyYYPlMYlv\GWyZX7k[Y51KG2jbn7ldi=> Mo\2NlUzOTB5OUW=
U266 MnexSpVv[3Srb36gRZN{[Xl? M{DjelUxOC95NUCgcm0> NGfFSZgzPC92ODDo MojhSG1UVw>? Mlv5[I94dnKnZ4XsZZRmeyCEaX2sJJBzcW6laYDhcIx6KHSqZTDFUEBqe2:ob4Lt NUXiblQzOjV{MEi4PFg>
RPMI8226 MVrGeY5kfGmxbjDBd5NigQ>? NXTJd5lGPTByL{e1NEBvVQ>? MonENlQwPDhiaB?= MnzlSG1UVw>? M4nxboRwf26{ZXf1cIF1\XNiQnntMEBxemmwY3nwZYxtgSC2aHWgSWwhcXOxZn;ycS=> NULwbJBvOjV{MEi4PFg>
MM.1S MmjESpVv[3Srb36gRZN{[Xl? MkjyOVAxNzd3MDDuUS=> MYeyOE81QCCq MWPEUXNQ NWjCfWJR\G:5boLl[5Vt[XSnczDCbY0tKHC{aX7jbZBidGy7IITo[UBGVCCrc3;mc5Ju M{PF[FI2OjB6OEi4
Clone A NFjEcGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV[wMlLjiJN4MDFOwG0> MnS2O|IhcA>? Mo\OSG1UVw>? MonDTWM2OD15LkWg{txO MoHhNlUzODh6OEK=
CX-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVP6U2ROOC5{4pETOlAh|ryP M33vNlczKGh? M1XzdmROW09? M164WGlEPTB;MT64JO69VQ>? NIXtXYszPTJyOEi4Ni=>
LS174T NFvYVotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\2TlAvOuLCk{[wJO69VQ>? NUHrSZdQPzJiaB?= MVzEUXNQ M4TC[GlEPTB;MUiuN{DPxE1? MYmyOVIxQDh6Mh?=
HT29 MXPBdI9xfG:|aYOgRZN{[Xl? NW\qUJpwOS93L{GwJO69VQ>? MoPHOFghcA>? NXr6SGtW[2G3c3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M4LmTFI2OTl{MUi4
SW480 M1fufGFxd3C2b4Ppd{BCe3OjeR?= NYTLVG15OS93L{GwJO69VQ>? Mn33OFghcA>? M{jVZoNifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NWDoVIQ6OjVzOUKxPFg>
Colo205 NEX5SnVCeG:ydH;zbZMhSXO|YYm= NFzFbIYyNzVxMUCg{txO NGC4SIM1QCCq Mn;JZ4F2e2W|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MnzWNlUyQTJzOEi=
Caco2 MYTBdI9xfG:|aYOgRZN{[Xl? NH20PWcyNzVxMUCg{txO NIP3UI81QCCq Mm[wZ4F2e2W|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MkjWNlUyQTJzOEi=
PCI-13 NH\4XpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLrO|IhcA>? MmXWSG1UVw>? MlvGS2k2OD1zNTFCtUAyNjhizszN NGX3XZYzPTF|OUO4Oy=>
PCI-15B MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLUO2FFPzJiaB?= NIHDS2NFVVOR M3r3NWdKPTB;MUGgxtEhPC53IN88US=> MUmyOVE{QTN6Nx?=
UM-SCC22B NGXjfGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\MSlFvPzJiaB?= NUTkR2wzTE2VTx?= M3fzNmdKPTB;MUmgxtEhOi57IN88US=> MnvmNlUyOzl|OEe=
UM-SCC47 Mn\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PYZlczKGh? NWPvc4cyTE2VTx?= M{nXWGdKPTB;MUmgxtEhOTJwMzFOwG0> M2[zZlI2OTN7M{i3
93-VU-147T NWLIcZpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX32Roh3PzJiaB?= MlnWSG1UVw>? M1TzXmdKPTB;ND6zJOKyKDNwNTFOwG0> NH:yTJQzPTF|OUO4Oy=>
UD-SCC2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DBWlczKGh? MWrEUXNQ MoT6S2k2OD1{ODFCtUAzNjlizszN MYeyOVE{QTN6Nx?=
UPCI:SCC90 NYPmSoRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrEO|A4OiCq NIqxZnVFVVOR MkjDS2k2OD14Lk[gxtEhOS53IN88US=> NYS3elFHOjVzM{mzPFc>
RPMI-8226  M3\3S2NmdGxiVnnhZoltcXS7IFHzd4F6 Mk\MNVI2NzJ3MD:1NFAhdk1? MXy0PIjDqA>? NYTBUoJPTE2VTx?= MWXk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mle1NlUxODh{MEK=
OPM-2  MYDD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MV:xNlUwOjVyL{WwNEBvVQ>? NV3CS|JVPDiqwrC= NWLTS3lbTE2VTx?= NGXQXHVl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NVHSb25lOjVyMEiyNFI>
RPMI-8226  MkPTRZBweHSxc3nzJGF{e2G7 NV2xU3J3OTJ3L{K1NE82ODBibl2= M{jpTFQ5cMLi MUDEUXNQ Ml3pbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MWCyOVAxQDJyMh?=
OPM-2  MmT4RZBweHSxc3nzJGF{e2G7 MVWxNlUwOjVyL{WwNEBvVQ>? MVS0PIjDqA>? MU\EUXNQ MWXpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MXiyOVAxQDJyMh?=
COG-LL-319 MVHGeY5kfGmxbjDBd5NigQ>? NETGfIwyODBibl2= MlzZNU8{NzZiaB?= MkDGSG1UVw>? MYrpcoR2[2W|IHPhd5Bie2VvZHXw[Y5l\W62IF3jcE0yKGOuZXH2ZYdm NX:0doo5OjR7NUG0O|I>
RS4;11 MX7GeY5kfGmxbjDBd5NigQ>? NHGwXJIyODBibl2= MV2xM|MwPiCq MmTkSG1UVw>? MX\pcoR2[2W|IHPhd5Bie2VvZHXw[Y5l\W62IF3jcE0yKGOuZXH2ZYdm NI\LfVkzPDl3MUS3Ni=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
PARP / c-PARP / cleaved caspase 3 ; 

PubMed: 21393866     


H146 cells were preincubated in normoxia or hypoxia (1% O2) for 18 hours prior to treatment with ABT-737 (89.1 nM ), after which cells were harvested for protein analysis by Western blot. 

Hif-1a; 

PubMed: 22006676     


Representative western blots for HIF-1α, PARP and cleaved caspase 3 in response to 24-72 hr exposure to ABT-737 in varying concentration in normoxia and hypoxia in 4 neuroblastoma cell lines. Actin is shown as a loading control. Blots are representative of 3 independent experiments.

γ-H2AX / p-ATM; 

PubMed: 21084274     


Induction of γ-H2AX and p-ATM by ABT-737. Cells were treated with 10 µmol/L ABT-737 for 24 hours and then maintained in fresh media for 1 or 2 more days prior to Western blot analysis.

21393866 22006676 21084274
Immunofluorescence
cytochrome C; 

PubMed: 26447615     


Immunocytochemistry revealed the release of mitochondrial cytochrome c (green) into the cytoplasm after ABT-737 exposure (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field.

Bax; 

PubMed: 26447615     


Immunocytochemistry revealed the mitochondrial translocation of Bax from the cytoplasm after ABT-737 treatment (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field C. To assess whether ABT-737 treatment has an effect on the dimerization of Bax, the levels of dimeric Bax were measured with or without ABT-737 treatment in MC-3 and HN22 cells.

Bim; 

PubMed: 26447615     


Immunocytochemistry revealed the mitochondrial translocation of Bim from the cytoplasm after ABT-737 treatment (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field.

AIF; 

PubMed: 25034785     


localization of apoptosis inducing factor (AIF) in LCSC pre-stained with Mitotracker Red and untreated or treated with 500 nM ABT-737 for 48 h. Magnification × 60, zoom × 3, bar 20 μm. 

p65 ; 

PubMed: 28846096     


BCL-xL dependent SVEC cells were treated with ABT-737 (10 μM) +/- Q-VD-Oph (30 μM) for 1 h, immunostained for p65 and analysed by confocal microscopy. TNF (20 ng/ml) was used as positive control for p65 nuclear translocation. Scale bar represents 30μM. Representative images from three independent experiments.

26447615 25034785 28846096
Growth inhibition assay
Cell viability; 

PubMed: 22311987     


Stably transfected K562 cells were treated with increasing concentrations of ABT-737, obatoclax, or maritoclax for 24 h. Cell viability was determined by measuring intracellular ATP levels with the CellTiter Glo assay.

22311987
ELISA
IL-6 / IL-8; 

PubMed: 21084274     


The secretion of IL-6 and IL-8 in PV-10 cells treated with DMSO, ABT-737 or enantiomer for 24 hours was determined by ELISA.

21084274
体内研究 ABT-737按30 mg/kg剂量作用于白血病模型,抑制白血病负担值达53% , 且明显延长鼠寿命。ABT-737不会引起血细胞数和血浆化学性质发生变话。[1] ABT-737延长移植BCL-2传感肿瘤的鼠寿命。[2] ABT-737按100 mg/kg剂量作用于ATLL鼠模型具有强抗癌活性。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

- 合并

荧光偏振实验:

测定GST-BCL-2蛋白家族与FITC-BIM BH3域结合的亲和力。100 nM GST-BCL-2家族融合蛋白和不同浓度 ABT-737在PBS温育2分钟。然后,加入20 nM FITC-BIM BH3 肽。进行荧光偏振,测定IC50值。
细胞实验:

[4]

- 合并
  • Cell lines: SCLC细胞系,包括NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR,和DMS114
  • Concentrations: 0.001-10 μM
  • Incubation Time: 48小时
  • Method:

    SCLC细胞在含10%人血浆的 100 μL 组织培养基的96孔培养板上处理48小时,使用MTS测定存活细胞。


    (Only for Reference)
动物实验:

[1]

- 合并
  • Animal Models: 注射ER细胞的Scid 鼠
  • Dosages: 20 mg/kg和30 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (122.93 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2%DMSO+40%PEG300+5%Tween80+53%ddH2O
2mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 813.43
化学式

C42H45ClN6O5S2

CAS号 852808-04-9
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    What’s the recommended method about reconstitution of the compound for in vivo animal study?

  • 回答:

    For oral administration, we suggest the vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W, at up to 30mg/ml; For injection, ABT-737 can be dissolved in 2% DMSO/50% PEG 300/5% Tween 80/ddH2O at 2.5 mg/ml.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

相关Bcl-2产品

Tags: 购买ABT-737 | ABT-737供应商 | 采购ABT-737 | ABT-737价格 | ABT-737生产 | 订购ABT-737 | ABT-737代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID